A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB)

  • Ryan, Jessica (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date25/03/25 → 24/03/30